OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
Last trade$2.53
Day change-$0.225 (-8.18%)
Day range$2.48 – $2.82
Volume143,769
Market cap$113M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$113.27M
Price / earnings
—
Price / book
0.72×
Price / sales
—
EV / sales
—
EV / EBITDA
0.58×
Profitability
Earnings per share
-$1.50
Return on assets
-37.02%
Return on equity
-39.21%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
18.84×
Quick ratio
18.84×
Cash ratio
17.23×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$47.94M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for OKUR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$4.29M
$4.29M
$3.91M
$3.41M
$3.59M
$3.71M
$3.99M
$4.34M
Research and development
$15.06M
$12.61M
$11.71M
$10.72M
$11.92M
$12.61M
$13.01M
$14.36M
Total operating expenses
$19.35M
$16.9M
$15.62M
$14.13M
$15.5M
$16.32M
$17M
$18.7M
Operating income
-$19.35M
-$16.9M
-$15.62M
-$14.13M
-$15.5M
-$16.32M
-$17M
-$18.7M
Interest expense
$0
$0
$0
-$6K
-$2K
$0
$0
-$57K
Income before taxes
-$17.85M
-$15.35M
-$15.16M
-$13.5M
-$14.7M
-$15.39M
-$15.93M
-$17.44M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$17.85M
-$15.35M
-$15.16M
-$13.5M
-$14.7M
-$15.39M
-$15.93M
-$17.44M
Net income attributable to common shareholders
-$17.85M
-$15.35M
-$15.16M
-$13.5M
-$14.7M
-$15.39M
-$15.93M
-$17.44M
EBITDA
-$19.3M
-$16.81M
-$15.51M
-$14.02M
-$15.39M
-$16.21M
-$16.88M
-$18.58M
Basic earnings per share
-$0.36
-$0.31
-$1.11
-$0.99
-$1.09
-$1.14
-$1.19
-$1.36
Diluted earnings per share
-$0.36
-$0.31
-$1.11
-$0.99
-$1.09
-$1.14
-$1.19
-$1.36
Recent news
Company coverage with links to the original publishers.
OnKure Therapeutics announced that senior management will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14-16, 2026, in New York. The company will host one-on-one investor meetings during the event. OnKure is advancing IND-enabling activities for next-generation PI3Kα inhibitor candidates OKI-345 and OKI-355, with IND submissions planned for the first half of 2027.
OnKure Therapeutics announced a virtual key opinion leader event on July 15, 2026, featuring prominent researchers to discuss the company's PI3Kα inhibitor drug candidates. The company is advancing two next-generation PI3Kα pan-mutant inhibitor programs (OKI-345 for breast cancer and OKI-355 for vascular anomalies) with plans to submit IND applications to the FDA in the first half of 2027.
OnKure Therapeutics announced positive preliminary data from its first-in-human trial of OKI-219, a PI3Kα inhibitor, showing good tolerability and favorable pharmacokinetics. The company plans to initiate a combination trial with fulvestrant in the second half of 2025.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.